CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines The Prevalence of Myocardial Bridging Associated with Coronary Endothelial Dysfunction in Patients with Chest Pain and Non-Obstructive Coronary Artery Disease Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes When, where, and how to target vascular inflammation in the post-CANTOS era? Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

Original ResearchFebruary 18, 2020 Vol 141, Issue 7

JOURNAL:Circulation. Article Link

The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk

A Agarwala, ED Michos, SS Virani et al. Keywords: atherosclerosis; coronary computed tomography angiography; imaging; preventive cardiology; risk stratification

ABSTRACT


Cardiovascular disease (CVD) is the leading cause of death among women in the United States. As compared with men, women are less likely to be diagnosed appropriately, receive preventive care, or be treated aggressively for CVD. Sex differences between men and women have allowed for the identification of CVD risk factors and risk markers that are unique to women. The 2018 American Heart Association/American College of Cardiology Multi-Society cholesterol guideline and 2019 American College of Cardiology/American Heart Association guideline on the primary prevention of CVD introduced the concept of risk-enhancing factors that are specific to women and are associated with an increased risk of incident atherosclerotic CVD in women. These factors, if present, would favor more intensified lifestyle interventions and consideration of initiation or intensification of statin therapy for primary prevention to mitigate the increased risk. In this primer, we highlight sex-specific CVD risk factors in women, stress the importance of eliciting a thorough obstetrical and gynecological history during cardiovascular risk assessment, and provide a framework for how to initiate appropriate preventive measures when sex-specific risk factors are present.